CA2186979A1 - Methodes pour analyser des antagonistes quant a leur capacite de modification de l'activite des recepteurs associes a la proteine g - Google Patents

Methodes pour analyser des antagonistes quant a leur capacite de modification de l'activite des recepteurs associes a la proteine g

Info

Publication number: CA2186979A1
Authority: CA; Canada
Prior art keywords: receptor; cells; activity; protein; receptors
Prior art date: 1996-10-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2186979

Other languages

English (en)

Inventor

Michael Dennis

Jean Labrecque

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-02

Filing date

1996-10-02

Publication date

1998-04-02

1996-10-02 Application filed by Individual filed Critical Individual

1996-10-02 Priority to CA 2186979 priority Critical patent/CA2186979A1/fr

1997-10-02 Priority to CA 2236205 priority patent/CA2236205A1/fr

1997-10-02 Priority to AU43742/97A priority patent/AU4374297A/en

1997-10-02 Priority to PCT/CA1997/000713 priority patent/WO1998014780A1/fr

1998-04-02 Publication of CA2186979A1 publication Critical patent/CA2186979A1/fr

Status Abandoned legal-status Critical Current

Links

230000000694 effects Effects 0.000 title abstract description 69
239000005557 antagonist Substances 0.000 title abstract description 59
238000000034 method Methods 0.000 title abstract description 33
238000012360 testing method Methods 0.000 title abstract description 22
102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract description 69
108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract description 69
239000000556 agonist Substances 0.000 abstract description 50
239000000126 substance Substances 0.000 abstract description 23
230000002269 spontaneous effect Effects 0.000 abstract description 18
238000012216 screening Methods 0.000 abstract description 4
239000003153 chemical reaction reagent Substances 0.000 abstract description 3
239000002547 new drug Substances 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 88
102000005962 receptors Human genes 0.000 description 76
108020003175 receptors Proteins 0.000 description 76
230000004044 response Effects 0.000 description 28
239000003814 drug Substances 0.000 description 27
229940079593 drug Drugs 0.000 description 26
229960004650 metergoline Drugs 0.000 description 23
WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 22
230000027455 binding Effects 0.000 description 21
239000003446 ligand Substances 0.000 description 21
241000701447 unidentified baculovirus Species 0.000 description 19
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 17
230000004913 activation Effects 0.000 description 17
208000015181 infectious disease Diseases 0.000 description 17
108091006027 G proteins Proteins 0.000 description 16
WYCMFCPHWDZHMR-UHFFFAOYSA-N 1-(4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-yl)-n,n-dimethylmethanesulfonamide Chemical compound C1=CC(C2CC(CN(C)C2C2)CS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 WYCMFCPHWDZHMR-UHFFFAOYSA-N 0.000 description 15
239000012636 effector Substances 0.000 description 15
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 14
102000030782 GTP binding Human genes 0.000 description 14
108091000058 GTP-Binding Proteins 0.000 description 14
239000013598 vector Substances 0.000 description 13
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 11
102000030621 adenylate cyclase Human genes 0.000 description 11
108060000200 adenylate cyclase Proteins 0.000 description 11
229960003955 mianserin Drugs 0.000 description 11
230000037361 pathway Effects 0.000 description 11
108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 9
238000003556 assay Methods 0.000 description 9
239000002299 complementary DNA Substances 0.000 description 9
230000007423 decrease Effects 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
102000014384 Type C Phospholipases Human genes 0.000 description 8
108010079194 Type C Phospholipases Proteins 0.000 description 8
231100000673 dose–response relationship Toxicity 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
230000008925 spontaneous activity Effects 0.000 description 8
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 7
229960004170 clozapine Drugs 0.000 description 7
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 7
150000002500 ions Chemical class 0.000 description 7
239000012528 membrane Substances 0.000 description 7
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
229910001424 calcium ion Inorganic materials 0.000 description 6
230000000862 serotonergic effect Effects 0.000 description 6
230000019491 signal transduction Effects 0.000 description 6
241000238631 Hexapoda Species 0.000 description 5
101150013372 Htr2c gene Proteins 0.000 description 5
230000009471 action Effects 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 5
229960000367 inositol Drugs 0.000 description 5
229940125425 inverse agonist Drugs 0.000 description 5
229960000423 loxapine Drugs 0.000 description 5
XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 5
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 5
238000005406 washing Methods 0.000 description 5
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000036755 cellular response Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
229960001186 methysergide Drugs 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
239000012148 binding buffer Substances 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
229960001076 chlorpromazine Drugs 0.000 description 3
210000002987 choroid plexus Anatomy 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
102000034286 G proteins Human genes 0.000 description 2
102100040756 Rhodopsin Human genes 0.000 description 2
108090000820 Rhodopsin Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
230000004075 alteration Effects 0.000 description 2
238000009395 breeding Methods 0.000 description 2
230000001488 breeding effect Effects 0.000 description 2
238000011072 cell harvest Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
150000001982 diacylglycerols Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
150000002617 leukotrienes Chemical class 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
229910001415 sodium ion Inorganic materials 0.000 description 2
238000012353 t test Methods 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000000103 Anorexia Nervosa Diseases 0.000 description 1
241001203868 Autographa californica Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000020925 Bipolar disease Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
101000878678 Homo sapiens Corticotropin-releasing factor receptor 1 Proteins 0.000 description 1
102400001355 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
101710151321 Melanostatin Proteins 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102400000064 Neuropeptide Y Human genes 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
108050002069 Olfactory receptors Proteins 0.000 description 1
102000012547 Olfactory receptors Human genes 0.000 description 1
101150037263 PIP2 gene Proteins 0.000 description 1
241000282320 Panthera leo Species 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
241000710961 Semliki Forest virus Species 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
208000027520 Somatoform disease Diseases 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000003693 atypical antipsychotic agent Substances 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229930003827 cannabinoid Natural products 0.000 description 1
239000003557 cannabinoid Substances 0.000 description 1
229940065144 cannabinoids Drugs 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
108091008690 chemoreceptors Proteins 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
231100000762 chronic effect Toxicity 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000009509 drug development Methods 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
239000006451 grace's insect medium Substances 0.000 description 1
108091005708 gustatory receptors Proteins 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000000412 mechanoreceptor Anatomy 0.000 description 1
108091008704 mechanoreceptors Proteins 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
210000000929 nociceptor Anatomy 0.000 description 1
108091008700 nociceptors Proteins 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
235000019645 odor Nutrition 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
208000027753 pain disease Diseases 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
150000003908 phosphatidylinositol bisphosphates Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
102000015130 taste receptor activity proteins Human genes 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000003051 thermoreceptor Anatomy 0.000 description 1
108091008689 thermoreceptors Proteins 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA 2186979 1996-10-02 1996-10-02 Methodes pour analyser des antagonistes quant a leur capacite de modification de l'activite des recepteurs associes a la proteine g Abandoned CA2186979A1 (fr)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
CA 2186979 CA2186979A1 (fr)	1996-10-02	1996-10-02	Methodes pour analyser des antagonistes quant a leur capacite de modification de l'activite des recepteurs associes a la proteine g
CA 2236205 CA2236205A1 (fr)	1996-10-02	1997-10-02	Procedes pour determiner la capacite des antagonistes a influer sur l'activite de recepteurs couples a des proteines g
AU43742/97A AU4374297A (en)	1996-10-02	1997-10-02	Methods of testing antagonists for their abilities to affect the activity of g protein-coupled receptors
PCT/CA1997/000713 WO1998014780A1 (fr)	1996-10-02	1997-10-02	Procedes pour determiner la capacite des antagonistes a influer sur l'activite de recepteurs couples a des proteines g

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2186979 CA2186979A1 (fr)	1996-10-02	1996-10-02	Methodes pour analyser des antagonistes quant a leur capacite de modification de l'activite des recepteurs associes a la proteine g

Publications (1)

Publication Number	Publication Date
CA2186979A1 true CA2186979A1 (fr)	1998-04-02

Family

ID=4159007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2186979 Abandoned CA2186979A1 (fr)	1996-10-02	1996-10-02	Methodes pour analyser des antagonistes quant a leur capacite de modification de l'activite des recepteurs associes a la proteine g

Country Status (3)

Country	Link
AU (1)	AU4374297A (fr)
CA (1)	CA2186979A1 (fr)
WO (1)	WO1998014780A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104594181A (zh) *	2013-10-31	2015-05-06	索列丹斯-弗莱西奈公司	用于土木工程结构的悬吊系统的缆索中的减振装置

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6682908B1 (en)	1998-07-10	2004-01-27	Merck & Co., Inc.	Mouse growth hormone secretagogue receptor
WO2000002919A1 (fr) *	1998-07-13	2000-01-20	Merck & Co., Inc.	Recepteurs et acides nucleiques en rapport avec un secretagogue d'hormone de croissance
GB0217551D0 (en) *	2002-07-30	2002-09-11	Amersham Biosciences Uk Ltd	Perturbation effect recognition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4138621A1 (de) *	1991-11-25	1993-06-17	Boehringer Ingelheim Int	Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
US5360735A (en) *	1992-01-08	1994-11-01	Synaptic Pharmaceutical Corporation	DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5677184A (en) *	1994-04-19	1997-10-14	Takeda Chemical Industries, Ltd.	CHO cells that express human LH-RH receptor
CA2135253A1 (fr) *	1994-11-07	1996-05-08	Michael Dennis	Depistage de composes grace a une fenetre d'activite independante du message chimique
CA2220715C (fr) *	1995-06-07	2004-11-02	Praecis Pharmaceuticals Incorporated	Dosage biologique fonctionnel pour les agonistes et antagonistes des recepteurs couples de proteine g
AU7622396A (en) *	1995-11-22	1997-06-11	Ciba-Geigy Ag	Therapeutic agents and screening method

1996
- 1996-10-02 CA CA 2186979 patent/CA2186979A1/fr not_active Abandoned
1997
- 1997-10-02 WO PCT/CA1997/000713 patent/WO1998014780A1/fr not_active Ceased
- 1997-10-02 AU AU43742/97A patent/AU4374297A/en not_active Abandoned

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104594181A (zh) *	2013-10-31	2015-05-06	索列丹斯-弗莱西奈公司	用于土木工程结构的悬吊系统的缆索中的减振装置
CN104594181B (zh) *	2013-10-31	2018-12-18	索列丹斯-弗莱西奈公司	用于土木工程结构的悬吊系统的缆索中的减振装置

Also Published As

Publication number	Publication date
WO1998014780A1 (fr)	1998-04-09
AU4374297A (en)	1998-04-24

Legal Events

Date	Code	Title	Description
1999-10-04	FZDE	Dead

Publication	Publication Date	Title
Rajagopal et al.	2010	Teaching old receptors new tricks: biasing seven-transmembrane receptors
Chan et al.	1995	Activation of type II adenylyl cyclase by the cloned μ‐opioid receptor: coupling to multiple G proteins
Schrage et al.	2015	The experimental power of FR900359 to study Gq-regulated biological processes
Sinnarajah et al.	2001	RGS2 regulates signal transduction in olfactory neurons by attenuating activation of adenylyl cyclase III
Park et al.	2004	Oligomerization of G protein-coupled receptors: past, present, and future
Vauquelin et al.	2005	G protein‐coupled receptors: a count of 1001 conformations
US7897386B2 (en)	2011-03-01	Cell-based assays for G-protein-coupled receptor-mediated activities
Rose et al.	2000	RGS7 is palmitoylated and exists as biochemically distinct forms
MX2011008129A (es)	2012-01-20	Nuevas lineas celulares y metodos.
Webb et al.	2005	D2 dopamine receptor activation of potassium channels is selectively decoupled by Gαi‐specific GoLoco motif peptides
CN101542288A (zh)	2009-09-23	鉴别trpv2的调节剂的组合物和方法
Okajima et al.	1997	Sphingosine 1-phosphate stimulates hydrogen peroxide generation through activation of phospholipase C-Ca2+ system in FRTL-5 thyroid cells: possible involvement of guanosine triphosphate-binding proteins in the lipid signaling
Patel et al.	2001	A molecular framework for two-step T cell signaling: Lck Src homology 3 mutations discriminate distinctly regulated lipid raft reorganization events
CA2135253A1 (fr)	1996-05-08	Depistage de composes grace a une fenetre d'activite independante du message chimique
Gu et al.	2002	The NMDA type glutamate receptors expressed by primary rat osteoblasts have the same electrophysiological characteristics as neuronal receptors.
Büküşoğlu et al.	1996	Agonist-specific conformational changes in the yeast α-factor pheromone receptor
Innamorati et al.	2006	The melanosomal/lysosomal protein OA1 has properties of a G protein‐coupled receptor
Godreau et al.	2003	Different isoforms of synapse-associated protein, SAP97, are expressed in the heart and have distinct effects on the voltage-gated K+ channel Kv1. 5
Fang et al.	2007	Optical biosensor differentiates signaling of endogenous PAR1 and PAR2 in A431 cells
Touhara et al.	2016	The GIRK1 subunit potentiates G protein activation of cardiac GIRK1/4 hetero-tetramers
Bernadyn et al.	2023	GPR114/ADGRG5 is activated by its tethered peptide agonist because it is a cleaved adhesion GPCR
CA2186979A1 (fr)	1998-04-02	Methodes pour analyser des antagonistes quant a leur capacite de modification de l'activite des recepteurs associes a la proteine g
Eglen et al.	2008	An overview of drug screening using primary and embryonic stem cells
Lidow et al.	2001	Receptor crosstalk protein, calcyon, regulates affinity state of dopamine D1 receptors
Ko et al.	2001	Inducible RGS2 is a cross-talk regulator for parathyroid hormone signaling in rat osteoblast-like UMR106 cells